Elafibranor
Author: Hannah Cohen
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Elafibranor (Genfit) is an oral peroxisome proliferator-activated receptor (PPAR) alpha-delta dual agonist. The medication activates PPAR-alpha and PPAR-delta, which control gene expression. Stimulating these receptors increases insulin sensitivity and fatty acid oxidation, which results in a reduction of fat buildup in the liver and leads to a decrease in fibrosis and inflammation. Elafibranor has also been shown to increase high-density lipoprotein levels, which may provide additional cardiovascular benefits.
Elafibranor has experienced mixed results in its Phase IIb GOLDEN trial due to the inclusion of non-alcoholic steatohepatitis (NASH) patients with Non-Alcoholic Fatty Liver Disease Activity Score (NAS) of 3 or above, rather than 4, which is usually required for NASH trials. This diluted the effect of the drug and likely contributed to the failure of elafibranor to meet the predefined primary endpoint of NASH resolution with no worsening fibrosis. However, a separate analysis that only included patients with a NAS score of 4 or above showed that significantly more patients in the 120mg elafibranor-treated group (19%) experienced the modified definition of NASH resolution compared to the placebo group (9%).
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 elafibranor : Non-alcoholic steatohepatitis (NASH)
LIST OF FIGURES
10 Figure 1: Datamonitor Healthcare’s drug assessment summary of elafibranor for NASH
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of elafibranor for NASH
13 Figure 3: Elafibranor sales for NASH across the US and five major EU markets, by country, 2018–27
LIST OF TABLES
6 Table 1: Elafibranor drug profile
8 Table 2: Late-phase trials of elafibranor for NASH
9 Table 3: Elafibranor for NASH – SWOT analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Ocaliva 
Sign up to the